Connect with us

Hi, what are you looking for?

Jewish Business News


Three way takeover battle- Teva: We can close Mylan deal in 2015

Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.

Teva CFO Eyal-Desheh

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) CFO Eyal Desheh remains upbeat about Teva’s attempts to buy Mylan N.V. (Nasdaq: MYL). At the same time, Mylan continues to oppose the takeover bid and believes that it is about to receive US Food and Drug Administration (FDA) approval to market a generic version of Copaxone, Teva’s flagship branded drug for treating multiple sclerosis.

Mylan CEO Heather Bresch and CFO John Sheehan took part yesterday in the Bank of America Merrill Lynch Health Care Conference and analyst Suman Kulkarni published presentations of Mylan and Teva afterwards. On Mylan he wrote, “On generic Copaxone, MYL stated that it went through the FDA’s response to TEVA’s eight citizen petitions and believes that its generic Copaxone meets all the criteria from a scientific perspective. MYL continues to expect approval at any time.”… [READ MORE]

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

GLOBES logo-eng (1)Published by Globes [online], Israel business news –



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News